MP66-16 EX-VIVO ASSESSMENT OF T CELL RESPONSE TO CHECKPOINT INHIBITION IN BLADDER AND KIDNEY TUMORS

INTRODUCTION AND OBJECTIVE:Checkpoint inhibitors (CPI) have emerged as a way to activate the immune system’s antitumor properties by blocking inhibitory signals such as programmed cell death ligand...